Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

SAN DIEGO and WOODCLIFF LAKE, N.J., Sept. 26, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical trial program will be presented in poster sessions at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society in Orlando, Florida. The posters highlighted below will be displayed in the Cypress Ballroom of the Orlando World Center Marriott on October 3, 2011, from 9:30 a.m. to 1:45 p.m. Eastern Time (ET) and from 3:15 p.m. to 6:30 p.m. ET. Authors will be available at the posters on October 3, 2011, from 12:30 p.m. to 1:30 p.m. ET.

- Effects of Lorcaserin, a Selective Serotonin 2C Agonist, on Cardiac Valvular Regurgitation in Obese and Overweight Patients During Exposures up to Two Years
Author: Neil J. Weissman, M.D., President of MedStar Health Research Institute and Professor of Medicine, Georgetown University
Poster number: 601-P

- Lorcaserin Reduced Weight and Improved Glycemic Control Across Patient Subgroups in Patients with Type 2 Diabetes
Author: Brian L. Raether, Arena's Senior Clinical Project Manager, Clinical Operations
Poster number: 603-P

- Safety and Efficacy of Lorcaserin: Comparison of Diabetic and Non-Diabetic Patient Populations
Author: Scott C. Stubbe, Arena's Associate Director, Clinical Operations
Poster number: 604-P

About LorcaserinLorcaserin is an investigational drug candidate intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (BMI >/= 30) or patients who are overweight (BMI >/= 27) and have at least one weight-related co-morbid condition. Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Partnership to Fight Chronic Disease (PFCD) released a public opinion poll ... new study analyzing the impact of increased cost sharing on patient ... to educate policy makers and the public on the costs of ... how the Iowa healthcare exchange could be ...
(Date:1/23/2015)... 2015  MedScope ( www.medscope.org ), the leading provider of ... Connected World magazine Connected World Award for ... can be used anywhere, anytime. The nomination was made ... In nominating MedScope, Landon Garner , Director of ...
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... IRVINE, Calif., May 26, 2011 Masimo (NASDAQ: ... present at the Goldman Sachs 32nd Annual Global Healthcare Conference ... 9, 2011, at 8:40 a.m. Pacific Time.  A live audiocast ... at www.masimo.com .  A replay of the audiocast will ...
... YORK, May 26, 2011 OTC Markets Group ... services company that provides the world,s largest electronic marketplace ... Verisante Technology Inc. (TSX.V: VRS; OTCQX: VRSEF), ... for the early detection of cancer, is now trading ...
Cached Medicine Technology:Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference 2Verisante Technology Inc. Joins OTCQX 2
(Date:1/22/2015)... Liberty University has received accreditation for its resident ... Council for Accreditation of Counseling & Related Educational Programs ... Counseling & Family Studies , is under the leadership of ... of Behavioral Sciences. Prior to the formation of the new ...
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... January 22, 2015 Juvent Sports ( ... the 2015 PGA Merchandise Show to bestow a Juvent ... female amateur golfer, Arlene McKitrick. The award commemorated and ... golf tournament win. She won her first amateur tournament ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... new treatment strategies for the disease , , THURSDAY, May 15 ... found in baked and fried goods, helps prevent prostate cancer ... of California, Los Angeles, scientists is believed to be the ... mimics human cancer. , The fat used in the study, ...
... invites shareholders and investors to listen to a broadcast ... and a discussion,of the outlook for the fourth quarter., ... over the Internet on,Thursday, May 15, 2008 at 4:30 ... Company,s website at http://www.pro-dex.com . Mark Murphy,Chief Executive ...
... ev3 Inc. (Nasdaq:,EVVV) today announced that Pat Spangler, senior ... at the 2008 FBR Capital Markets,Spring Investor Conference on ... p.m. Central Time and 11:20 a.m. Pacific Time). The ... at the Grand Hyatt,Hotel, located at 109 East 42nd ...
... 15 Cleveland Clinic announced today that,the Cleveland ... Reserve,University is providing all its students with full ... Approaching its fifth year in existence, the Cleveland ... training of physician scientists,who are capable of furthering ...
... 2008 Losing weight may help resolve erectile ... today at the 103rd Annual Scientific Meeting of ... cause sexual dysfunction independent of other common confounders, ... from researchers in Boston and Philadelphia, sexual function ...
... 75-80 with prostate-specific antigen (PSA) levels less than 3 ... cancer screenings, according to new research presented today during ... (AUA). Johns Hopkins University researchers found that men in ... 3 ng/ml or above had an increasing probability of ...
Cached Medicine News:Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2Health News:Cleveland Clinic Lerner College of Medicine to Offer Full Tuition Scholarships for All Students 2Health News:Cleveland Clinic Lerner College of Medicine to Offer Full Tuition Scholarships for All Students 3Health News:Regular prostate-specific antigen screening may be discontinued in certain elderly populations 2
For the quantitative in vitro determination of Urea in serum, plasma and urine....
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
Medicine Products: